Skip to main content

Security report for novonordisk.pl

Novo Nordisk · Healthcare · Poland

Low risk. 1 critical or high finding in Security headers.

Security score

81/100

Risk levelLow

0–100, higher is better. How it is calculated

Novo Nordisk Polska is the Polish branch of Novo Nordisk, a leading global healthcare company specializing in innovative therapies for chronic diseases such as diabetes, obesity, haemophilia, and menopause. The website serves Polish patients, healthcare professionals, and job seekers, providing comprehensive information about the company's scientific approach, heritage, and business activities. The company holds a strong market position with over 100 years of history and operates as an enterprise-level pharmaceutical business.

Scanned

NIS2 and GDPR posture

GDPR outside view
88/ 100 · Low
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

1 finding rated critical or high. Fix these first.

  1. Security headers

    Security headers are instructions your web server sends to every visitor’s browser. Missing ones leave visitors more exposed to attacks such as clickjacking and injected scripts.

    • High

      Missing Content-Security-Policy header

      Controls resources the browser is allowed to load

      What to do: Implement a Content-Security-Policy appropriate for your application

      • ASVS V3.4.3
      • OWASP Secure Headers: OWASP Secure Headers Project recommends Content-Security-Policy: default-src 'self'; form-action 'self'; base-uri 'self'; object-src 'none';…

Need hands-on remediation? Email guard@offseq.com

Keep watching novonordisk.pl

This scan found 16 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. See sample alerts.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
95
Security headers
65
Email security
60
DNS health
80
Network security
100
GDPR outside view
88
Average
81

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

The company leverages a pharmaceutical business model focused on research, development, and distribution of healthcare products. The website reflects a mature digital presence with clear branding, professional content, and targeted navigation for different user groups. The absence of direct contact emails or phone numbers on the homepage suggests a preference for contact forms and controlled communication channels. The site supports recruitment efforts with detailed career information and job listings. The global footprint and local adaptation indicate a well-established partnership ecosystem and strategic market presence in Poland.

Security posture

The website demonstrates a good security posture with HTTPS enforcement, modern security headers, and cookie consent mechanisms compliant with GDPR. However, explicit security policies, incident response contacts, and vulnerability disclosure information are not published, which could be improved to enhance transparency and readiness. No vulnerabilities or exposed sensitive data were detected in the analyzed content. The use of trusted third-party services like Adobe Analytics and OneTrust further supports a compliant and secure environment.

Recommendations

  1. Publish a dedicated security policy and incident response page with clear contact channels.
  2. Implement and publicize a vulnerability disclosure program or security.txt file.
  3. Provide verified company contact emails and phone numbers for security and general inquiries.
  4. Regularly review and update third-party scripts to mitigate potential vulnerabilities.
  5. Enhance transparency on certifications, compliance frameworks, and data retention policies.
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Novo Nordisk
Description
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. The company focuses on developing and delivering innovative therapies for people suffering from serious chronic diseases such as diabetes, obesity, haemophilia, and menopause.
Key services
Innovative therapies for diabetes type 1 and 2, Obesity treatment, Hemophilia care, Menopause related therapies, Local health initiatives, Pharmaceutical product information and instructions
Content quality
good
Branding
consistent

Technology

Stack
Adobe Helix RUM, Vue.js, OneTrust Cookie Consent, Adobe Launch, Typekit Fonts
Frameworks
Vue.js
Performance
moderate
Mobile
good
Accessibility
good
SEO
good

Security

Observed score
85/100
Good practices seen
  • HTTPS enforced
  • Cookie consent with OneTrust
  • No exposed sensitive data in HTML
  • Use of modern JS frameworks

Analytics and tracking

Services
Adobe Analytics
Tracking level
moderate
Privacy practices
good

Advertising

Tracking pixels
Adobe Analytics
Marketing tools
Adobe Launch, OneTrust Cookie Consent
Transparency
good

Site quality

Design
good
User experience
good
Content relevance
good
Navigation
good
Professionalism
good
Trustworthiness
high

Key observations

  1. Website is fully accessible and not blocked by WAF
  2. Content is in Polish language targeting Polish audience
  3. Strong use of modern web technologies and frameworks
  4. Cookie consent and privacy policy are implemented properly
  5. No direct contact emails or phone numbers found on homepage; contact form available
  6. No explicit security or incident response contact information published
  7. WHOIS data is not publicly available for this .pl domain
  8. Website branding and content consistent with Novo Nordisk corporate identity
Technical notes

Notes

The website is built on Adobe Experience Manager CMS with Vue.js framework and integrates Adobe Launch for tag management and OneTrust for cookie consent. The site uses Typekit for fonts and Adobe Helix RUM for performance monitoring. The technical implementation is modern and supports good mobile responsiveness, accessibility, and SEO optimization. Performance is moderate with room for improvement in loading speed. The site architecture is clear and navigation is user-friendly, supporting a positive user experience.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with novonordisk.pl. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review novonordisk.pl.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.